Clinical trial · no report yet · Phase 3
FIRST-308
Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma
- NCT05948475 ↗
- Active, not recruiting
- TransThera Sciences (Nanjing), Inc.
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 4 | |
| Bluesky threads | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase III, Randomized, Controlled, Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib VS Physician's Choice in Subjects With FGFR-altered, Chemotherapy- and FGFR Inhibitor-Cholangiocarcinoma
- Phase
- Phase 3
- Status
- Active, not recruiting
- Conditions
- Cholangiocarcinoma
- Interventions
- Tinengotinib 8 mg; Tinengotinib 10 mg; Physician's Choice
- Arms
- Tinengotinib 8 mg QD · Experimental
- Tinengotinib 10 mg QD · Experimental
- Physician's Choice · Active comparator
- Enrollment
- 200 (estimated)
- Primary outcomes
- Part A: Incidence, duration, and severity of adverse events (AEs)
- Part B: PFS by BICR
- Sponsor
- TransThera Sciences (Nanjing), Inc.
- Start
- Dec 20, 2023
- Primary completion
- Dec 2026 (estimated)
- Results posted
- No
- Registry record
- NCT05948475 · updated Jul 6, 2026